Interestingly, PD-L1 in exosomes and more specifically soluble PD-L1 appears as a credible predictive and prognostic marker to monitor treatment efficacy in a myriad of cancers including breast, gastric, urothelial, esophageal or hepatocellular cancers [124–130]. This evidence concerns the gene CD274 and hepatocellular carcinoma.